<scp>BRAF</scp> and <scp>MEK</scp> inhibitor therapy eliminates Nestin‐expressing melanoma cells in human tumors
Deon B. Doxie(Vanderbilt University), Jonathan M. Irish(Vanderbilt University), Kimberly B. Dahlman(Vanderbilt University), Jocelyn S. Gandelman(Vanderbilt University), Caroline E. Roe(Vanderbilt University), Allison R. Greenplate(California University of Pennsylvania), Kirsten E. Diggins(Vanderbilt University), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Mark C. Kelley(Vanderbilt University)
Cited by 14
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k